Metagenomi Therapeutics, Inc. (MGX)

Market Cap	50.82M -14.5%
Revenue (ttm)	22.33M -50.7%
Net Income	-85.89M
EPS	-2.30
Shares Out	37.65M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	180,701
Open	1.340
Previous Close	1.310
Day's Range	1.300 - 1.375
52-Week Range	1.240 - 3.950
Beta	0.64
Analysts	Buy
Price Target	8.00 (+492.59%)
Earnings Date	May 11, 2026

About MGX

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company’s lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 9, 2024
• Employees: 119
• Stock Exchange: NASDAQ
• Ticker Symbol: MGX
• Website: https://metagenomi.co

Financial Performance

In 2025, Metagenomi Therapeutics's revenue was $25.21 million, a decrease of -51.79% compared to the previous year's $52.30 million. Losses were -$87.87 million, 12.6% more than in 2024.

Analyst Summary

According to 4 analysts, the average rating for MGX stock is "Buy." The 12-month stock price target is $8.0, which is an increase of 492.59% from the latest price.

Price Target

$8.0

(492.59% upside)

Analyst Consensus: Buy